The current trading zone is interesting to the point that investors should pay attention to the stock and anticipate a return of the underlying upward trend. Investors have an opportunity to buy the stock and target the $ 56.9.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The company has solid fundamentals for a short-term investment strategy.
Chemours Co accounts for 5.18 % of our USA Portfolio. A trade is currently open since 02/21/2018 with a purchase price of $ 50.23. Discover the other 19 stocks of the USA portfolio managed by the 4-traders portfolio management team.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Its low valuation, with P/E ratio at 9.26 and 8.34 for the ongoing fiscal year and 2019 respectively, makes the stock pretty attractive with regard to earnings multiples.
Sales forecast by analysts have been recently revised upwards.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
For the past twelve months, EPS forecast has been revised upwards.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The tendency within the weekly time frame is positive above the technical support level at 46.08 USD
The company's earnings releases usually do not meet expectations.
The company is not the most generous with respect to shareholders' compensation.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.